

# Supporting Information

## Implementing Fluorescence Anisotropy Screening and Crystallographic Analysis to Define PKA Isoform-Selective Activation by cAMP Analogs

**Simon H.J. Brown<sup>1,5</sup>, Cecilia Y. Cheng<sup>1</sup>, S. Adrian Saldanha<sup>1</sup>, Jian Wu<sup>1</sup>, Howard B Cottam<sup>3</sup>, Banumathi Sankaran<sup>4</sup>, and Susan S. Taylor<sup>1,2</sup>**

<sup>1</sup>Department of Chemistry and Biochemistry, <sup>2</sup>Department of Pharmacology and Howard Hughes Medical Institute, <sup>3</sup>Moore's Cancer Center, University of California, San Diego, La Jolla, CA 92037-0654, <sup>4</sup>Lawrence Berkeley National Lab, Advanced Light Source, Berkeley, CA 94720, and <sup>5</sup>School of Health Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia.

e-mail: [staylor@ucsd.edu](mailto:staylor@ucsd.edu). Telephone: (858) 534-3677. Fax: (858) 534-8193.



**Figure S1.** Electron Density of HE33 in RII $\beta$ -HE33 crystal structures. The  $2F_o-F_c$  map is rendered at  $1\sigma$ . Domain A is shown on the left and domain B is shown on the right.